174 related articles for article (PubMed ID: 25033809)
41. Novel Ras antagonist blocks human melanoma growth.
Jansen B; Schlagbauer-Wadl H; Kahr H; Heere-Ress E; Mayer BX; Eichler H; Pehamberger H; Gana-Weisz M; Ben-David E; Kloog Y; Wolff K
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14019-24. PubMed ID: 10570191
[TBL] [Abstract][Full Text] [Related]
42. Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.
Elad G; Paz A; Haklai R; Marciano D; Cox A; Kloog Y
Biochim Biophys Acta; 1999 Dec; 1452(3):228-42. PubMed ID: 10590312
[TBL] [Abstract][Full Text] [Related]
43. Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells.
Santen RJ; Lynch AR; Neal LR; McPherson RA; Yue W
Anticancer Drugs; 2006 Jan; 17(1):33-40. PubMed ID: 16317288
[TBL] [Abstract][Full Text] [Related]
44. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
Egozi Y; Weisz B; Gana-Weisz M; Ben-Baruch G; Kloog Y
Int J Cancer; 1999 Mar; 80(6):911-8. PubMed ID: 10074926
[TBL] [Abstract][Full Text] [Related]
45. Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice.
Jansen B; Heere-Ress E; Schlagbauer-Wadl H; Halaschek-Wiener J; Waltering S; Moll I; Pehamberger H; Marciano D; Kloog Y; Wolff K
J Mol Med (Berl); 1999 Nov; 77(11):792-7. PubMed ID: 10619439
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome.
Katzav A; Kloog Y; Korczyn AD; Molina V; Blank M; Shoenfeld Y; Chapman J
Immunobiology; 2003; 207(1):47-50. PubMed ID: 12638903
[TBL] [Abstract][Full Text] [Related]
47. FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice.
Goldberg L; Israeli R; Kloog Y
Cell Death Dis; 2012 Mar; 3(3):e284. PubMed ID: 22419113
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats.
da Silva Morais A; Saliez A; Leclercq I; Horsmans Y; Stärkel P
Clin Sci (Lond); 2008 Jan; 114(1):73-83. PubMed ID: 17678500
[TBL] [Abstract][Full Text] [Related]
49. Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation.
Neeman R; Abramovitch S; Sharvit E; Elad-Sfadia G; Haklai R; Kloog Y; Reif S
Dig Dis Sci; 2014 Oct; 59(10):2462-9. PubMed ID: 24942325
[TBL] [Abstract][Full Text] [Related]
50. Hybrid molecule from Farnesylthiosalicylic acid-diamine and phenylpropenoic acid as Ras-related signaling inhibitor with potent antitumor activities.
Ling Y; Wang Z; Wang X; Li X; Wang X; Zhang W; Dai H; Chen L; Zhang Y
Chem Biol Drug Des; 2015 Feb; 85(2):145-52. PubMed ID: 25043275
[TBL] [Abstract][Full Text] [Related]
51. Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib.
Faigenbaum R; Haklai R; Ben-Baruch G; Kloog Y
Oncotarget; 2013 Feb; 4(2):316-28. PubMed ID: 23530112
[TBL] [Abstract][Full Text] [Related]
52. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid.
Marom M; Haklai R; Ben-Baruch G; Marciano D; Egozi Y; Kloog Y
J Biol Chem; 1995 Sep; 270(38):22263-70. PubMed ID: 7673206
[TBL] [Abstract][Full Text] [Related]
53. Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.
Wu B; Yuan Y; Liu J; Shang H; Dong J; Liang X; Wang D; Chen Y; Wang C; Zhou Y; Jing H; Cheng W
J Nanobiotechnology; 2021 Jun; 19(1):177. PubMed ID: 34118951
[TBL] [Abstract][Full Text] [Related]
54. Ras inhibition attenuates myocardial ischemia-reperfusion injury.
Pando R; Cheporko Y; Haklai R; Maysel-Auslender S; Keren G; George J; Porat E; Sagie A; Kloog Y; Hochhauser E
Biochem Pharmacol; 2009 May; 77(10):1593-601. PubMed ID: 19426696
[TBL] [Abstract][Full Text] [Related]
55. An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.
Furuse J; Kurata T; Okano N; Fujisaka Y; Naruge D; Shimizu T; Kitamura H; Iwasa T; Nagashima F; Nakagawa K
Cancer Chemother Pharmacol; 2018 Sep; 82(3):511-519. PubMed ID: 29992354
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells.
Du R; Sullivan DK; Azizian NG; Liu Y; Li Y
BMC Cancer; 2021 Mar; 21(1):237. PubMed ID: 33676427
[TBL] [Abstract][Full Text] [Related]
57. Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis.
Barkan B; Cox AD; Kloog Y
Oncotarget; 2013 Feb; 4(2):256-68. PubMed ID: 23530091
[TBL] [Abstract][Full Text] [Related]
58. Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells.
Beiner ME; Niv H; Haklai R; Elad-Sfadia G; Kloog Y; Ben-Baruch G
Int J Gynecol Cancer; 2006; 16 Suppl 1():200-6. PubMed ID: 16515591
[TBL] [Abstract][Full Text] [Related]
59. Stringent structural requirements for anti-Ras activity of S-prenyl analogues.
Aharonson Z; Gana-Weisz M; Varsano T; Haklai R; Marciano D; Kloog Y
Biochim Biophys Acta; 1998 Feb; 1406(1):40-50. PubMed ID: 9545527
[TBL] [Abstract][Full Text] [Related]
60. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
Sacco E; Spinelli M; Vanoni M
Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
